In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Pharmaceuticals Group PLC

http://www.shire.com

Latest From Shire Pharmaceuticals Group PLC

Genfit Pivots To Opposite End Of The Liver Disease Spectrum

Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.

Restructuring Business Strategies

Asia Deal Watch: Eisai Advances Portfolio Focus With Divestiture Of Two Products To DKSH

Plus deals involving Dong-A/Polifarma, Intas/Syna, Kissei/Synmosa, Ono/Memo, Takeda/Shionogi, Fosun/Lilly and JW Therapeutics/2seventy bio.

Deal Watch Business Strategies

FTC May Go After Pharma Bundling, Rebates, Patent Processes With Reactivation of Section 5

Agency restores long dormant enforcement of section of FTC Act prohibiting businesses from using ‘unfair methods of competition,’ expanding types of corporate behavior subject to enforcement action.

Enforcement Legal Issues

Japan Q2 Roundup: Mixed Bag For Majors But Forex Provides Boost

Japan's top pharma firms logged generally strong performances for mainstay global drugs in the fiscal period ended 30 September, with the weakened yen adding substantially to figures for those with large overseas sales. Astellas and Eisai are among those awaiting important global-first approvals for potential blockbusters.

Japan Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced BioHealing, Inc. (renamed Shire Regenerative Medicine)
    • AesRX LLC
    • Baxalta Incorporated
    • BIKAM Pharmaceuticals Inc.
    • Chatham Therapeutics
    • Dyax Corp.
    • FerroKin BioSciences, Inc.
    • Fibrotech Therapeutics
    • Foresight Biotherapeutics Inc.
    • Gambro AB
    • Immuno-US
    • Jerini AG
    • Lotus Tissue Repair
    • Lumena Pharmaceuticals
    • Meritage Pharma, Inc.
    • Movetis NV
    • New Pervasis Therapeutics, Inc.
    • NPS Pharmaceuticals, Inc.
    • Premacure AB
    • Prism Pharmaceuticals, Inc.
    • River Pharmaceuticals
    • Roberts Pharmaceutical Corporation
    • SARcode Corporation
    • SuppreMol GmbH
    • Synovis Life Technologies, Inc.
    • Transkaryotic Therapies, Inc.
    • ViroPharma Inc.
UsernamePublicRestriction

Register